Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | FPR3 | P25089 | 2/20 | 0.39 |
| ▸ | FPR2 | P25090 | 2/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | IL2 | P60568 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.38 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.38 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23347014 | 0.89 | SMN1; SMN2 (0.43) | SMN1; SMN2NAAATTRIL2NAMPT | |
| SCHEMBL6849179 | 0.89 | PTGS1 (0.47) | SMN1; SMN2NAAATTRIL2NAMPT | |
| SCHEMBL21659263 | 0.88 | NAMPT (0.42) | SMN1; SMN2NAAATTRIL2NAMPT | |
| SCHEMBL20936656 | 0.88 | SMN1; SMN2 (0.40) | SMN1; SMN2NAAATTRIL2NAMPT | |
| SCHEMBL2779228 | 0.88 | NAAA (0.55) | SMN1; SMN2NAAAGNAI3GNAO1GNAI1 | |
| SCHEMBL14872066 | 0.88 | NAAA (0.55) | SMN1; SMN2NAAAGNAI3GNAO1GNAI1 | |
| SCHEMBL21118924 | 0.87 | SMN1; SMN2 (0.40) | SMN1; SMN2NAAATTRIL2NAMPT | |
| SCHEMBL20841156 | 0.87 | SMN1; SMN2 (0.40) | SMN1; SMN2NAAATTRIL2NAMPT | |
| SCHEMBL11990499 | 0.86 | SMN1; SMN2 (0.53) | SMN1; SMN2NAAAGNAI3GNAO1GNAI1 | |
| SCHEMBL17739999 | 0.86 | NAAA (0.48) | SMN1; SMN2NAAAGNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230097252-A1 | LIGASE FUSION PROTEINS AND APPLICATION THEREOF | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2023-03-30 | — | — | US | disclosed |
| US-20230062712-A1 | ANTI-ASGR1 ANTIBODY CONJUGATES AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20220362396-A1 | AMINO-PYRAZINECARBOXAMIDE COMPOUNDS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2022-11-17 | — | — | US | disclosed |
| US-11453870-B2 | Ligase fusion proteins and application thereof | GENEQUANTUM HEALTHCARE (SUZHOU) CO. LTD. (CN) | 2022-09-27 | — | — | US | disclosed |
| WO-2022006327-A1 | ANTI-ASGR1 ANTIBODY CONJUGATES AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. (US) | 2022-01-06 | — | — | WO | disclosed |
| WO-2022006340-A1 | ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. (US) | 2022-01-06 | — | — | WO | disclosed |
| WO-2021102332-A1 | TGFBETAR2 INHIBITOR-LRRC15 ANTIBODY CONJUGATES AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. (US) | 2021-05-27 | — | — | WO | disclosed |
| WO-2021067644-A1 | COMBINATION THERAPY WITH IMMUNE STIMULATORY CONJUGATES | SILVERBACK THERAPEUTICS, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| WO-2021011834-A1 | ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| WO-2020056192-A1 | ANTIBODY CONJUGATES OF TOLL-LIKE RECEPTOR AGONISTS | SILVERBACK THERAPEUTICS, INC. (US) | 2020-03-19 | — | — | WO | disclosed |
| WO-2019079357-A1 | TNIK MODULATORS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. (US) | 2019-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230097252-A1 | LIGASE FUSION PROTEINS AND APPLICATION THEREOF | LIG1, LIG3, STUB1 | SMN1; SMN2 3761/4885NAAA 3364/4885FPR3 4125/4885 |
| US-20230062712-A1 | ANTI-ASGR1 ANTIBODY CONJUGATES AND USES THEREOF | ASGR1, HAVCR2, FCGR2A | SMN1; SMN2 3457/4885NAAA 3852/4885FPR3 672/4885 |
| US-20220362396-A1 | AMINO-PYRAZINECARBOXAMIDE COMPOUNDS, CONJUGATES, AND USES THEREOF | TGFBR2, SMAD2, ACVR2A | SMN1; SMN2 3976/4885NAAA 1711/4885FPR3 1824/4885 |
| US-11453870-B2 | Ligase fusion proteins and application thereof | LIG1, LIG3, STUB1 | SMN1; SMN2 3761/4885NAAA 3364/4885FPR3 4125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.